A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Stage 1 is the earliest stage of multiple myeloma. People with stage 1 have lower levels of beta-2-microglobulin (below 3.5 ...

They found enhanced knockout efficiencies for beta-2-microglobulin (B2M), a protein crucial in antigen presentation and immune response, and T cell receptor alpha chain (TRAC), a key immune ...